VRDN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Viridian Therapeutics Inc (VRDN) does not present a compelling buy opportunity for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock is facing competitive challenges, declining analyst price targets, and lacks strong positive catalysts in the near term. While the company has shown some financial improvement, the risks outweigh the potential rewards given the current market sentiment and technical indicators.
The technical indicators for VRDN are mixed to bearish. The MACD is positive and expanding, suggesting some bullish momentum, but the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 14.155, with resistance at 15.278. Overall, the technical outlook does not strongly support a buy decision.
The company has a strong cash position of $875 million, which provides financial flexibility. Revenue increased significantly by 83.33% YoY in Q4 2025, and the gross margin remains at 100%. The company's therapeutic candidates have met primary endpoints in trials, showing potential for future growth.
Additionally, Kopp Family Office recently reduced its stake, signaling decreased confidence. Hedge funds and insiders are neutral, showing no strong support for the stock.
In Q4 2025, the company reported a net loss of $120.36 million, which improved by 50.96% YoY. EPS also improved by 28.28% YoY to -1.27. While the revenue growth of 83.33% YoY is impressive, the company remains unprofitable, and its net loss is substantial.
Analysts maintain a generally positive outlook with Outperform and Buy ratings, but there is a clear trend of declining price targets. Recent adjustments reflect concerns over competitive pressures and the commercial viability of Viridian's therapeutic candidates. The current price targets range from $24 to $37, significantly higher than the current pre-market price of $14.29, but the downward revisions indicate caution.
